A series of benzindazole-4,9-quinones was tested for growth-inhibitory effects on Cryptosporidium parvum in vitro and in vivo. Most compounds showed considerable activity at concentrations from 25 to 100 µM. For instance, at 25 µM the derivatives 5-hydroxy-8-chloro-N 1 -methylbenz[f]-indazole-4,9-quinone and 5-chloro-N 2 -methylbenz[f]indazole-4,9-quinone inhibited growth of C. parvum 78-100%, and at 50 µM seven of the 23 derivatives inhibited growth ≥90%. The activity of the former two compounds was confirmed in a T-cell receptor α (TCR-α)-deficient mouse model of chronic cryptosporidiosis. In these mice, the mean infectivity scores (IS) in the caecum were 0.63-0.20, whereas in sham-treated mice the score was 1.44 (P < 0.05). There were similar differences in IS in the ileum, where the score for treated mice was 1.12-0.20 and that for mice receiving no drug was 1.32. There was no acute or chronic toxicity for any compound tested in vivo.
Introduction
Cryptosporidium parvum is an intracellular parasite of human enterocytes that may cause watery diarrhoea, cramps, nausea and anorexia, which is generally self-limiting in immunocompetent hosts. However, cryptosporidiosis can be lifethreatening to immunocompromised individuals, including patients undergoing immunosuppressive therapy or organ transplantation or who are infected with the human immunodeficiency virus (HIV). Here, the disease is prolonged, and diarrhoea may persist for months to years. As yet, there is no specific prevention or therapy available for cryptosporidiosis. [1] [2] [3] [4] Although hundreds of drugs have been tested against cryptosporidiosis, 5 none have proved effective enough to warrant extended clinical trials in AIDS patients. Drugs now used clinically include paromomycin, 6 nitazoxanide, 7 azithromycin plus paromomycin, 8 roxithromycin 9 and 'highly active antiretroviral therapy' (HAART). Again, none is sufficiently efficacious to be recommended universally, and most of them either have significant side effects or do not prevent relapse. 10 Therefore, there is an urgent need for both innovative and pharmaceutically improved drugs to treat this AIDS-associated disease.
A series of benzindazole-4,9-quinones (BIQs) initially developed to treat visceral leishmaniasis have recently been tested against C. parvum in vitro and in vivo. Structurally, BIQs are naphthoquinones that possess an additional imidazole ring. 11 Naphthoquinones and other related quinoids are one of the major drug classes with significant activity against parasitic protozoa like Leishmania, Trypanosoma and Plasmodium. 12 Many naphthoquinones have been isolated from plant or microbial sources, but in most cases their potential usefulness has been limited by cytotoxicity and low bioavailability. In contrast, the BIQs tested here showed no, or only moderate, cytotoxicity. For this reason, BIQs have been tested as lead compounds in a murine model of chronic cryptosporidiosis.
Materials and methods

Compounds
BIQs were synthesized by one of us (H. L.). Structures and >95% purity were determined by both nuclear magnetic resonance spectroscopy (H/C-NMR) and high-performance liquid chromatography (HPLC 11, 13 ). All compounds were first dissolved in dimethylsulphoxide (DMSO), aliquoted and then stored frozen until used, when they were diluted with phosphate-buffered saline (PBS) to the desired concentration (25-100 µM).
In vitro testing for anticryptosporidial activity
A well-established in vitro assay was used to test the efficacy of these inhibitors against C. parvum. 14 Briefly, human ileocaecal epithelial cells (HCT-8; ATCC CCL 244) were cultured in 75 cm 2 tissue culture flasks in a maintenance medium consisting of RPMI 1640 supplemented with 10% Opti-MEM (Gibco-BRL), 2% fetal bovine serum (FBS) and 2 mM L-glutamine at 37°C in a humidified, 5% CO 2 -enriched atmosphere. [15] [16] [17] Ninety-six-well flat-bottomed microtitre plates were seeded with 5.0 × 10 4 HCT-8 cells/well and incubated for 14-24 h. For infection, the maintenance medium was replaced by 100 µL/well parasite growth medium 17 containing 3.0 × 10 4 sterilized oocysts. Non-viable, negative controls consisted of the same number of oocysts that had been frozen and thawed using liquid nitrogen and a 37°C water bath. Parasites were allowed to invade host cells for 90 min at 37°C, and any non-invading parasites were removed by rinsing once with warm PBS. After rinsing, 150 µL of fresh growth medium containing drugs at appropriate concentrations was added to each well. Negative controls contained drug diluent and growth medium only. Four to eight replicate wells were used for each experimental condition. All compounds were tested at least twice in separate experiments.
Infected HTC-8 monolayers were incubated for 48 h, then fixed with 8% formalin in PBS (pH 7.3) for 2 h at room temperature. After fixation, plates were blocked for 1 h with 1% bovine serum albumin (BSA) containing 0.002% Tween-20 in PBS, and they were then labelled for 30 min with rat polyclonal antibodies directed against C. parvum membrane proteins. A goat-anti-rat polyvalent antiserum conjugated with horseradish peroxidase was used in combination with a 3,3′,5,5′,-tetra-methyl-benzidine (TMB) substrate kit to check for colour development at λ abs 630 using a BioTek EL311s ELISA plate reader. Each plate contained four or more positive controls including paromomycin 200 µg/mL, which consistently inhibits parasite growth 60-70% in this assay. Inconclusive data, i.e. those in which the optimal parasite densities deviated more than ±3 standard deviations from the mean, were excluded from the calculations. Cytotoxicity for host cells was evaluated by cell death and/or detachment from the tissue culture plastic, as well as by an MTT cytotoxicity assay as described previously. 14 
In vivo testing for anticryptosporidial activity
Experimental design. Mice deficient in T-cell receptor α (TCR-α) are incapable of clearing C. parvum infections. 18 Therefore, they are useful for screening lead compounds against cryptosporidiosis. Oocysts were isolated and purified from the faeces of calves experimentally inoculated with C. parvum as described previously. 19 Neonatal TCR-α-deficient mice were infected by gavage with 1 × 10 3 C. parvum oocysts in 100 µL of 0.15 M PBS at 7 days of age. Mice were then treated either with PBS (controls) or test compounds beginning at 10 days of age. The drugs were administered orally by gavage twice daily for 6 or 7 days using a 24G animal feeding needle at a dose of 0.67 mg/kg body weight. Mice were euthanized at 21 days of age when intestinal biopsies were performed, and sections from them were examined both for the presence of C. parvum and for histopathological changes due to the infection.
Assessment of infection.
Intestinal sections from the distal ileum and caecum were fixed in 10% formalin and embedded in paraffin. Histological sections (4 µm) were cut, stained with haematoxylin-eosin and examined microscopically both for intracellular stages of C. parvum and for pathological lesions due to the infection. Infectivity scores (IS) were determined as described previously. 20, 21 Briefly, a score of 0 means that no intracellular stages of C. parvum were detected; 1 means that a few enterocytes containing parasites were observed; and 2 means that many intestinal cells contained asexual, intracellular stages of C. parvum. Scores were determined by examining at least 100 fields in individual tissue sections. Means were calculated for each treatment group, and the data were expressed as group mean ± S.E.M.
Assay for cytopathic activity against host cells. Briefly, uninfected HCT-8 monolayers were incubated in several concentrations of experimental drugs for 48 h and were then exposed to 50 µL of medium containing 0.8 mg/mL sodium 3′-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis-(4-methoxy-6-nitro)benzene-sulphonic acid hydrate (XTT; Sigma) and 100 µM phenazine methosulphate (Sigma) for 1 h at 37°C, so that a change in colour could develop as described previously. 21 The absorbance was read at λ 450 using a BioTek EL311s ELISA plate reader.
Statistical significance
Mean IS were analysed by one-way analysis of variance followed by Tukey-Kramer multiple comparison tests, or 2 × 2 contingency tables were formulated and the percentage infected analysed by Fisher's Exact Test. Data were considered significant when P < 0.05.
Results
The structure and in vitro and in vivo activities of BIQs against C. parvum are shown in Figure 1 and Tables 1-3 . When BIQs were tested in vitro at 10, 25, 50 and 100 µM concentrations, 13 out of 23 significantly inhibited growth of the pathogen (>40% at 50 µM), and only moderate or no toxicity for HCT-8 host cells was observed (data not shown).
The most efficacious BIQs were N 1 -methylbenzindazole-4,9-quinones, which were effective at concentrations of <50 µM. BIQs were considered highly active if growth was inhibited 90% at 25- -23) showed <30% inhibition at any concentration and were therefore considered inactive. Among the most active BIQs, only 8 and 13 were cytotoxic, and then only at 100 µM, the highest concentration tested. All moderately active or inactive BIQs were non-toxic to host cells. Table 1 for details. Table 1 . Benzindazole-4,9-quinones and naphthindazole-4-9-quinones (see Figure 1 for 
Discussion
Perhaps not unexpectedly, these data indicate that BIQs have potential activity against C. parvum both in vitro and in a murine model of chronic cryptosporidiosis that mimics the disease in AIDS patients. An extensive analysis of the in vitro inhibition of C. parvum growth indicated that N 1 -methylbenzindazole-4,9-quinones 2-6, 10 and 17 are efficacious and show promise as lead BIQs. When compared with moderately active or inactive analogues, antiparasitic activity appeared to be associated with the parent structure, and only minor substitutions on the aromatic ring are permitted if activity is to be sustained. The introduction of oxygen groups (BIQs 6 and 10), halogenation (BIQs 5 and 13) or methylation (BIQ 8) increased activity against C. parvum. Activity was reduced when N 1 -methylbenzindazole-4,9-quinones were substituted by N 2 -methylated analogues, especially at lower drug doses. This is noted for compounds 6 (N 1 ) and 20 (N 2 ), both having a hydroxy group at C-5. Specifically, at 25 µM concentrations the change from N 1 -to N 2 -methylation resulted in a drop from 100% anticryptosporidial activity to <10%. Although the limited number of BIQs tested prevented an exact evaluation of why N 1 -methylation of the imidazole ring is important, the trend for reduced activity by N 2 analogues is quite clear.
Depending upon the substitution pattern, non-alkylated compounds were either highly active (BIQ 2, 100%) or inactive (BIQ 1, <10%) at 25 µM. Interestingly, even minor modifications like an ethyl substitution at N 1 (BIQs 14-16) reduced the anticryptosporidial activity to <10%. Analysis of the BIQ rates of inhibition at 50 µM also showed that introducing an aromatic (BIQ 22) or cyclohexane (BIQ 23) ring on the parent structure drastically reduced activity to <10%. Taking a closer look at the substitution pattern on the aromatic ring revealed that hydroxy groups or halogenation at positions C-5 and C-8 seemed to contribute significantly to activity against C. parvum. Both peri-substitution on the aromatic ring and meta-substition of a methyl or hydroxy group lead to a marked loss in activity, e.g. at 50 µM the inhibition of Table 2 . In vitro anticryptosporidial activity of benzindazole-4,9-quinones and naphthindazole-4-9-quinones a a Values indicate percentage growth inhibition of C. parvum related to untreated controls; Tx, non-specific cytotoxicity as indicated by cytopathic effects on host cells. b Benzindazole-4,9-quinones as listed in Table 1 ; structures shown in Figure 1 <10  43  71  13  79  100  99  Tx  14  <10  <10  <10  <10  15  <10  <10  <10  <10  16  <10  <10  <10  <10  17  64  86  90  93  18  <10  <10  34  100  19  17  78  99  100  20  <10  <10  44  100  21  <10  <10  <10  <10  22  <10  <10  <10  <10  23  <10  <10  <10  <10  Paro  <10  <10  19  40   Table 3 . In vivo anticryptosporidial activity of selected benzindazole-4,9-quinones a a Values indicate an infectivity score as described in Materials and methods; differences compared with PBS-treated mice are significant at P < 0.05. b Benzindazole-4,9-quinones as listed in Table 1 and illustrated in Figure 1 growth by BIQs 7, 11 and 12 was <10%, 45% and 43%, respectively. As mentioned previously, additional testing of selected BIQs in a TCR-α-deficient murine model of chronic cryptosporidiosis that mimics the disease in AIDS patients confirmed the efficacy observed in vitro. Remarkably, treatment with BIQ 13 resulted in a nearly complete cure of experimental mouse infections. There were no significant side effects at any dose tested, even including oral dosing at 169 µg/kg body weight.
As with simple naphthoquinones, the presence of redox groups may contribute to the considerable activity and low toxicity of BIQs against C. parvum and plant naphthoquinones against species of Leishmania and Plasmodium. 12, 22 By virtue of structural analogy to naphthoquinones and their mode of action, BIQs are postulated to inhibit parasite growth by causing disruption of mitochondrial electron transport, 23 especially at sites III (bc 1 complex) and IV (cytochrome c oxidase) where quinones are known to play a role. 24, 25 For instance, it is well documented that trypanosomatids can generate radicals from redox cycling of ortho-naphthoquinones 26 and that naphthoquinones inhibit the consumption of oxygen by Leishmania species. 27 Although the remarkable efficacy of BIQs for C. parvum both in vitro and in vivo was unknown, using the mitochondria-specific vital fluorescent dyes DIOC 6 , MitoTracker Green FM, Rhodamine B and Rhodamine 123 (Molecular Probes), we have recently shown that the relic mitochondrion of C. parvum 28 possesses a membrane potential (∆Ψ mt ) that can be disrupted by 1 nM KCN or 100 µM oligomycin (J. S. Keithly, unpublished results). Therefore, as in trypanosomatids and other apicomplexans, 29, 30 it is likely that some part of BIQ efficacy against C. parvum is related to mitochondrial function.
In contrast to the widely tested naphthoquinones, the introduction of an imidazole ring in BIQs seemed to be important for reducing toxicity. Therefore, in order to develop a safe and effective lead compound, the precise target and mechanism of action of this pharmacophore needs to be determined. We are currently testing lead BIQs for their ability to inhibit O 2 uptake by sporozoites of C. parvum and to disrupt ∆Ψ mt as measured by the dissipation of fluorescence of mitochondriaspecific vital dyes. Similar methods have been used successfully both in vitro and in vivo to determine the mode of action of mitochondrial inhibitors against the apicomplexans Plasmodium yoelii and Toxoplasma gondii, 29, 30 as well as trypanosomatids. 24 In the future, molecular modelling might also be useful for synthesizing more efficacious BIQs.
In conclusion, our study shows that BIQs exhibit interesting anticryptosporidial properties with low toxicity for mammalian host cells. These results may have implications for other intracellular apicomplexans like Plasmodium and Toxoplasma, as well as the kinetoplastids Leishmania and Trypanosoma. In vivo experiments in a murine model confirmed the in vitro results. Additional drug formulations must now be tested and experimental procedures varied to substantiate further and possibly improve the already appreciable antiparasitic activities of BIQs in vivo. The anticryptosporidial potential of the BIQs described here may well contribute to the search for new and selective therapies against cryptosporidiosis. This is especially important, because a safe and efficacious treatment for this AIDSassociated opportunistic disease is still not available.
